Choose Your Language:
On July 28, 2022, TSF was joined by 100 friends of the Foundation to celebrate 8 years of illuminating the darkness of NMOSD and MOGAD at The Envoy Hotel’s Lookout Rooftop overlooking Boston’s stunning city line. Congratulations to Lauren Michaels (TSF Board Member) and Jil Sharpe (TSF Chief of Staff) for hosting and organizing such a beautiful event.
Our platinum sponsor was Horizon Therapeutics, a biopharmaceutical company focused on researching, developing, and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. In June 2020, The U.S. Food and Drug Administration approved Horizon Therapeutics’ Uplizna (inebilizumab-cdon) injection for intravenous use for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients with a particular antibody (patients who are anti-aquaporin-4 or AQP4 antibody positive).
Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. In August 2020, Genentech announced that the U.S. Food and Drug Administration (FDA) approved Enspryng™(satralizumab-mwge) as the first and only subcutaneous treatment for adults living with anti-aquaporin-4 (AQP4) antibody positive neuromyelitis optica spectrum disorder (NMOSD).
We can’t wait to see you at TSF’s 6th Annual Gala set to take place at The Newbury Hotel in Boston on April 22, 2023.
Want to get involved? Email [email protected]